Delta-8 THC in France: legal framework and health risks

Delta-8 tetrahydrocannabinol (Δ8-THC) is a cannabinoid naturally present in trace amounts in the hemp plant (generally less than 0.1%). Its chemical structure is extremely close to that of delta-9 THC, the molecule responsible for the psychoactive effect of cannabis. The difference lies in the position of a double bond on the carbon chain. This molecular proximity produces comparable psychoactive effects, although users describe them as slightly less intense.

Because the natural concentration in hemp is very low, products sold under the "delta-8" label are obtained by chemical synthesis from CBD: a laboratory conversion using solvents and acid catalysts. This manufacturing route places them among the semi-synthetic cannabinoids, alongside HHC, H4CBD and THCP, which flourished on the European market between 2022 and 2024.

Unlike the United States, where delta-8 benefited from a grey area created by the 2018 Farm Bill, France has never authorised its sale. Two regimes apply to it.

First, delta-8 THC is an isomer of THC. Tetrahydrocannabinol and its isomers have long appeared on the list of narcotics annexed to the order of 22 February 1990, pursuant to articles L.5132-7 and R.5132-86 of the Public Health Code. Manufacturing, importing, possessing and selling any product containing it therefore constitutes a criminal offence.

Second, the ANSM accelerated the movement to ban neo-cannabinoids from 2023 onwards. The order of 11 June 2023 classified HHC, HHC-O and HHC-P on the narcotics list. A second order, published in the Official Journal on 3 June 2024, added H4CBD, H2CBD, HHCPO, THCP, THCA and 10-OH-HHC. The entire family of psychoactive semi-synthetic derivatives previously sold in shops thus became illegal.

The penalties involved are heavy: narcotics trafficking (article 222-37 of the Criminal Code) carries up to ten years' imprisonment and a fine of €7,500,000 for retailers; possession and use expose the individual to one year's imprisonment and a €3,750 fine, or a fixed penalty of €200.

The ANSM justifies its decision on three grounds documented in its June 2023 statement and confirmed in 2024.

Established psychoactive effects. The centres for the evaluation and information on pharmacodependence (CEIP-A) collected more than 200 reports of serious poisonings between January and May 2024, linked to semi-synthetic cannabinoids. The symptoms described — disorientation, acute anxiety, tachycardia, vomiting — match THC use, sometimes at unpredictable doses.

Addictive risk comparable to cannabis. Animal data and early clinical feedback suggest a dependence potential close to that of delta-9. Regular consumption sustains tolerance and a risk of withdrawal.

Unregulated manufacturing processes. Because the CBD → delta-8 conversion uses solvents (toluene, heptane, hexane), finished products frequently contain concerning chemical residues. In 2024 ANSES relayed around twenty alerts from French poison control centres about CBD products contaminated with synthetic cannabinoids or residual solvents.

The CBD sold in French shops is non-psychoactive and derived from hemp varieties listed in the common European catalogue. Delta-8 is psychoactive and illegal. Medical cannabis, rolled out generally since 2025 by the ANSM across five clinical indications, is a medicine dispensed by hospital pharmacies — it should be confused neither with CBD nor with synthetic cannabinoids.

The roadside saliva test detects THC, but also its isomers and metabolites. Delta-8 use therefore produces a positive test in the same way as conventional cannabis. Article L.235-1 of the Highway Code penalises "driving a vehicle after using substances or plants classified as narcotics" with 2 years' imprisonment, a €4,500 fine, the loss of 6 licence points and licence suspension.

This position was confirmed by the Court of Cassation in its ruling of 21 June 2023 (no. 22-85.530): the possible legality of the product consumed does not exempt the driver, once the test is positive. For delta-8, which is illegal on top of that, a second offence is added to the driving charge.

The line between legal CBD and a banned product is not always obvious from the label. Here are a few markers for French consumers.

• Mention of a cannabinoid beyond CBD/CBG/CBN. If you read "delta-8", "HHC", "H4CBD", "THCP" or "HHCO" on the packaging, the product has been banned in France since 2024.
• Promises of psychoactive effects. Wording such as "euphoric", "intense relaxation", "mild high" or "floating effect" betrays a risky product. Legal CBD produces no psychoactive effect.
• Vague origin. A product with no accessible certificate of analysis (CoA), no identified hemp variety, no batch number and no traceability should be set aside.
• Abnormally low price. The real cost of controlled French CBD (THC testing, traceability, forthcoming Novel Food compliance) limits aggressive discounting.

In 2024 the DGCCRF carried out more than 1,200 inspections of the CBD market, with an infringement rate of around 15%, mainly relating to misleading claims and the presence of banned cannabinoids. Consumers can report a suspicious product through the SignalConso platform.

If you have consumed a product labelled "delta-8", "HHC" or "THCP" and experience adverse effects — palpitations, acute anxiety, disorientation, intense nausea — call 15 or your regional poison control centre. Keep the packaging: it helps doctors identify the substance.

For users who turned to these derivatives in search of a psychoactive effect, it is worth repeating that no legal alternative exists in France outside a medical framework. Wellness CBD produces no euphoric effect. If you are dealing with problematic consumption, the Drogues Info Service helpline (0 800 23 13 13, anonymous and free) offers specialist support.

CBD is not a medicine. If you have any doubt about a product, or in the event of adverse effects linked to cannabinoid consumption, consult a healthcare professional or contact a poison control centre.

• Delta-8 THC is banned in France under the Public Health Code and the ANSM order of 3 June 2024.
• Almost all "delta-8" products are semi-synthetic, produced by a chemical conversion of CBD using potentially hazardous solvents.
• Five closely related cannabinoids have also been classified as narcotics since 2023: HHC, HHC-O, HHC-P (June 2023), then H4CBD, H2CBD, HHCPO, THCP, THCA, 10-OH-HHC (June 2024).
• Consuming delta-8 produces a positive saliva test for THC: driving is punishable under article L.235-1 of the Highway Code.
• Wellness CBD (≤ 0.30% THC in the finished product, non-psychoactive) remains legal following the Conseil d'État ruling of 29 December 2022.
• Reporting a suspicious product: the SignalConso platform (DGCCRF). Health emergency: 15 or a poison control centre.

• Conseil d'État, interim ruling, 24 Jan. 2022, no. 460055 — primary
• ANSM — HHC classified as a narcotic, June 2023 — primary
• ANSM — New cannabinoids classified as narcotics, May 2024 — primary